Blood test could predict which kidney cancer drugs work best
NCT ID NCT03185039
Summary
This study aims to determine if measuring two specific proteins (MMP2 and MMP9) in blood can help predict how well patients with metastatic kidney cancer will respond to anti-angiogenic drugs like Sunitinib or Pazopanib. Researchers will compare protein levels in 50 patients receiving these drugs against patients with earlier-stage cancer who are not receiving this treatment. The goal is to identify biomarkers that might help doctors choose the most effective treatments for individual patients in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Paoli Calmettes
Marseille, 13009, France
Conditions
Explore the condition pages connected to this study.